Travere Therapeutics
TVTX
238 hedge funds and large institutions have $2.41B invested in Travere Therapeutics in 2025 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 27 closing their positions.
203% more call options, than puts
Call options by funds: $77.4M | Put options by funds: $25.5M
107% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 27
62% more capital invested
Capital invested by funds: $1.49B → $2.41B (+$920M)
13% more funds holding
Funds holding: 211 → 238 (+27)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.21% less ownership
Funds ownership: 113.24% → 113.03% (-0.21%)
10% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 80
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$55.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.3M |
| 3 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$30.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.9M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$40.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$19M |
| 3 |
Renaissance Technologies
New York
|
-$14M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.2M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$11.5M |
TVTX Hedge Fund Activity: Q3 2025 in Review
238 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2025, worth a combined $2.41B — up 62% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new TVTX positions and 27 closed out — a net gain of 29 holders — while 72 added to existing stakes and 80 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $55.7M. The largest seller was Armistice Capital, cutting an estimated $40.5M.
- 238 institutional investors held Travere Therapeutics (TVTX) as of Q3 2025, up from 211 in Q2 2025.
- Funds reported $2.41B of Travere Therapeutics stock for Q3 2025, up 62% quarter-over-quarter.
- 56 funds opened new Travere Therapeutics positions in Q3 2025 and 27 closed out, a net change of +29 holders.
- The largest Travere Therapeutics buyer in Q3 2025 was Perceptive Advisors, an estimated $55.7M added.
- The largest Travere Therapeutics seller in Q3 2025 was Armistice Capital, an estimated $40.5M sold.
Based on aggregated 13F filings for Q3 2025.